Quotient Limited Reports Positive MosaiQ Results From Performance Evaluation Study For Blood Grouping

Quotient Limited Reports Positive MosaiQ™ Results From Performance Evaluation Study for Blood Grouping

  • Root-cause investigation completed and corrective actions implemented
  • Performance evaluation study for antigen typing achieves targeted endpoints
  • Completion of European field trials expected in the first half of 2017

JERSEY, Channel Islands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported positive results from its MosaiQ™ performance evaluation study for antigen typing.  The Company continues to expect European field trials for MosaiQ™, for blood grouping and the initial disease screening panel, to be completed during the first half of 2017.

“We believe the positive results from the performance evaluation study demonstrate the power and potential of MosaiQ™.  Prior to commencing the study, we successfully completed the root-cause investigation previously announced and implemented all necessary corrective actions,” said Paul Cowan, Chairman and Chief Executive Officer of Quotient.  “Results from the performance evaluation study demonstrate our confidence in being able to transfer existing blood grouping tests to the MosaiQ™ platform and that the MosaiQ™ instrument is robust.”

MosaiQ™, Quotient’s next-generation automation platform for blood grouping and donor disease screening, is a transformative and highly disruptive testing platform designed to address the $3.4 billion global transfusion diagnostics market.  Utilizing a single instrument platform, MosaiQ™ is designed to undertake a comprehensive characterization of donor and patient blood (i.e. blood grouping) and all mandated serological and molecular disease screening tests for donor blood.  Adoption of  MosaiQ™ by donor- and patient-testing laboratories is expected to deliver substantial efficiencies and material cost savings, while also improving patient outcomes.

Antigen Typing Performance Evaluation Study - Results

Microarrays incorporating assays to identify ABO, Rhesus and Kell blood-group antigens were used in the performance evaluation study.  Below is a summary of the results.

 Blood
Group
  Specificity   Total
Samples
  True
Positive
  False
Positive
  True
Negative
  False
Negative
  Concordance
(%)

  Sensitivity
(%)

  Specificity 
(%)

 ABO  A  804  297  0  507  0  100.0%  100.0%  100.0%
    B  804  93  0  711  0  100.0%  100.0%  100.0%
 Rhesus   D  804  631  0  169  4  99.5%  99.4%  100.0%
    C  804  502  0  302  0  100.0%  100.0%  100.0%
    c  804  657  0  143  4  99.5%  99.4%  100.0%
    E  804  264  0  540  0  100.0%  100.0%  100.0%
    e  804  781  0  22  1  99.9%  99.9%  100.0%
 Kell  K  804  78  0  726  0  100.0%
MORE ON THIS TOPIC